Author

A. Goenka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Hu· 2 shared C. I. Wells· 2 shared R. B. Riggins· 2 shared X. Song· 2 shared A. Picado· 1 shared B. Erdogdu· 1 shared B. R. Haddad· 1 shared C. A. Ferrer· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Hu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SGC-CLK-1 (CAF-170) a chemical probe for the Cdc2-Like kinases CLK1, CLK2, and CLK4

D. Tiek, C. I. Wells, M. Schroder, X. Song, C. A. Ferrer, A. Goenka, R. Iglesia, M. Lu, B. Hu, F. Kwarcinski, P. Sintha, C. de Silva, M. A. Hossain, A. Picado, W. Zuercher, , D. Drewry

This paper identifies and characterizes SGC-CLK-1, a potent inhibitor of CLK1, CLK2, and CLK4, showing its selectivity and effects on SR protein phosphorylation and localization.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas

D. M. Tiek, B. Erdogdu, R. Razaghi, L. Jin, N. Sadowski, C. Alamillo-Ferrer, J. R. Hogg, B. R. Haddad, D. H. Drewry, C. I. Wells, J. E. Pickett, X. Song, A. Goenka, B. Hu, S. L. Goldlust, , R. B. Riggins

This study identifies guanine mutations in TMZ-resistant gliomas that disrupt G4 structures and splice sites, creating vulnerabilities targeted by G4 stabilizers and splicing inhibitors.

bioRxiv · Nov 21, 2021Cancer Biology